Monitoring Molecular Response to TKI Therapy in Chronic Myelogenous Leukemia
This information was originally presented on March 15, 2014, at the NCCN 19th Annual Conference: Advancing the Standard of Cancer Care™ held in Hollywood, Florida.
This activity is designed to meet the educational needs of physicians, nurses, pharmacists, and other clinical professionals who manage patients with cancer.
Following this activity, participants should be able to:
- Integrate into professional practice the key updates of the NCCN Guidelines related to chronic myelogenous leukemia
- Explain the rationale, methodology, and recommendation for monitoring molecular response to TKI therapy using QPCR (IS)
- Utilize the results of molecular monitoring and mutational analysis to select the appropriate TKI therapy
Jerald P. Radich, MD
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance
- 0.75 Participation
- 0.85 Nurse
- 0.75 Pharmacist
- 0.75 Physician